A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct acting antiviral therapies. A yeast-based immunother...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas H King, Charles B Kemmler, Zhimin Guo, Derrick Mann, Yingnian Lu, Claire Coeshott, Adam J Gehring, Antonio Bertoletti, Zi Z Ho, William Delaney, Anuj Gaggar, G Mani Subramanian, John G McHutchison, Shikha Shrivastava, Yu-Jin L Lee, Shyamasundaran Kottilil, Donald Bellgrau, Timothy Rodell, David Apelian
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0101904
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125110045835264
author Thomas H King
Charles B Kemmler
Zhimin Guo
Derrick Mann
Yingnian Lu
Claire Coeshott
Adam J Gehring
Antonio Bertoletti
Zi Z Ho
William Delaney
Anuj Gaggar
G Mani Subramanian
John G McHutchison
Shikha Shrivastava
Yu-Jin L Lee
Shyamasundaran Kottilil
Donald Bellgrau
Timothy Rodell
David Apelian
author_facet Thomas H King
Charles B Kemmler
Zhimin Guo
Derrick Mann
Yingnian Lu
Claire Coeshott
Adam J Gehring
Antonio Bertoletti
Zi Z Ho
William Delaney
Anuj Gaggar
G Mani Subramanian
John G McHutchison
Shikha Shrivastava
Yu-Jin L Lee
Shyamasundaran Kottilil
Donald Bellgrau
Timothy Rodell
David Apelian
author_sort Thomas H King
collection DOAJ
description Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct acting antiviral therapies. A yeast-based immunotherapy (Tarmogen) platform was used to make a vaccine candidate expressing hepatitis B virus (HBV) X, surface (S), and Core antigens (X-S-Core). Murine and human immunogenicity models were used to evaluate the type and magnitude of HBV-Ag specific T cell responses elicited by the vaccine. C57BL/6J, BALB/c, and HLA-A*0201 transgenic mice immunized with yeast expressing X-S-Core showed T cell responses to X, S and Core when evaluated by lymphocyte proliferation assay, ELISpot, intracellular cytokine staining (ICS), or tumor challenge assays. Both CD4+ and CD8+ T cell responses were observed. Human T cells transduced with HBc18-27 and HBs183-91 specific T cell receptors (TCRs) produced interferon gamma (IFNγ following incubation with X-S-Core-pulsed dendritic cells (DCs). Furthermore, stimulation of peripheral blood mononuclear cells (PBMCs) isolated from CHB patients or from HBV vaccine recipients with autologous DCs pulsed with X-S-Core or a related product (S-Core) resulted in pronounced expansions of HBV Ag-specific T cells possessing a cytolytic phenotype. These data indicate that X-S-Core-expressing yeast elicit functional adaptive immune responses and supports the ongoing evaluation of this therapeutic vaccine in patients with CHB to enhance the induction of HBV-specific T cell responses.
format Article
id doaj-art-7e27258ef8564bc4a5d1fac67125fcb8
institution OA Journals
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-7e27258ef8564bc4a5d1fac67125fcb82025-08-20T02:34:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10190410.1371/journal.pone.0101904A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.Thomas H KingCharles B KemmlerZhimin GuoDerrick MannYingnian LuClaire CoeshottAdam J GehringAntonio BertolettiZi Z HoWilliam DelaneyAnuj GaggarG Mani SubramanianJohn G McHutchisonShikha ShrivastavaYu-Jin L LeeShyamasundaran KottililDonald BellgrauTimothy RodellDavid ApelianChronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct acting antiviral therapies. A yeast-based immunotherapy (Tarmogen) platform was used to make a vaccine candidate expressing hepatitis B virus (HBV) X, surface (S), and Core antigens (X-S-Core). Murine and human immunogenicity models were used to evaluate the type and magnitude of HBV-Ag specific T cell responses elicited by the vaccine. C57BL/6J, BALB/c, and HLA-A*0201 transgenic mice immunized with yeast expressing X-S-Core showed T cell responses to X, S and Core when evaluated by lymphocyte proliferation assay, ELISpot, intracellular cytokine staining (ICS), or tumor challenge assays. Both CD4+ and CD8+ T cell responses were observed. Human T cells transduced with HBc18-27 and HBs183-91 specific T cell receptors (TCRs) produced interferon gamma (IFNγ following incubation with X-S-Core-pulsed dendritic cells (DCs). Furthermore, stimulation of peripheral blood mononuclear cells (PBMCs) isolated from CHB patients or from HBV vaccine recipients with autologous DCs pulsed with X-S-Core or a related product (S-Core) resulted in pronounced expansions of HBV Ag-specific T cells possessing a cytolytic phenotype. These data indicate that X-S-Core-expressing yeast elicit functional adaptive immune responses and supports the ongoing evaluation of this therapeutic vaccine in patients with CHB to enhance the induction of HBV-specific T cell responses.https://doi.org/10.1371/journal.pone.0101904
spellingShingle Thomas H King
Charles B Kemmler
Zhimin Guo
Derrick Mann
Yingnian Lu
Claire Coeshott
Adam J Gehring
Antonio Bertoletti
Zi Z Ho
William Delaney
Anuj Gaggar
G Mani Subramanian
John G McHutchison
Shikha Shrivastava
Yu-Jin L Lee
Shyamasundaran Kottilil
Donald Bellgrau
Timothy Rodell
David Apelian
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
PLoS ONE
title A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
title_full A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
title_fullStr A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
title_full_unstemmed A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
title_short A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
title_sort whole recombinant yeast based therapeutic vaccine elicits hbv x s and core specific t cells in mice and activates human t cells recognizing epitopes linked to viral clearance
url https://doi.org/10.1371/journal.pone.0101904
work_keys_str_mv AT thomashking awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT charlesbkemmler awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT zhiminguo awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT derrickmann awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT yingnianlu awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT clairecoeshott awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT adamjgehring awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT antoniobertoletti awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT zizho awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT williamdelaney awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT anujgaggar awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT gmanisubramanian awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT johngmchutchison awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT shikhashrivastava awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT yujinllee awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT shyamasundarankottilil awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT donaldbellgrau awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT timothyrodell awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT davidapelian awholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT thomashking wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT charlesbkemmler wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT zhiminguo wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT derrickmann wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT yingnianlu wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT clairecoeshott wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT adamjgehring wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT antoniobertoletti wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT zizho wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT williamdelaney wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT anujgaggar wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT gmanisubramanian wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT johngmchutchison wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT shikhashrivastava wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT yujinllee wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT shyamasundarankottilil wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT donaldbellgrau wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT timothyrodell wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance
AT davidapelian wholerecombinantyeastbasedtherapeuticvaccineelicitshbvxsandcorespecifictcellsinmiceandactivateshumantcellsrecognizingepitopeslinkedtoviralclearance